Skip to content
AVIRAtea Pharmaceuticals, Inc.

Earnings

When Atea Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

31 quarters. Mar 31, 2019 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 4, after the close

Thu, Mar 4, 2027in 108 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 25 – Mar 9

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2021 n/m, Q3 2021 n/m, Q2 2021 n/m, Q1 2021 n/m
Net income
-$44.87M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 9, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$32.16M
    N/M
    EPS
    -$0.40
    N/M
    On November 9, 2026, Atea announced that it entered into a credit facility agreement with Hercules Capital, Inc. for up to $200 million.
  2. Q2 2026Aug 12, 2026, after the closeThe release0.2%by the close of Aug 13
    Revenue
    —
    —
    Net income
    -$32.93M
    N/M
    EPS
    -$0.41
    N/M
  3. Q1 2026May 12, 2026, after the closeThe release16.9%by the close of May 13
    Revenue
    —
    —
    Net income
    -$45.44M
    N/M
    EPS
    -$0.57
    N/M
  4. Q4 2025Mar 5, 2026, after the closeThe release+11.1%by the close of Mar 6
    Revenue
    —
    —
    Net income
    -$44.87M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 9, 2026 · after-hoursNov 9, 202640 d10-Q——-$0.40—
Q2 2026Jun 30, 2026Aug 12, 2026 · after-hoursAug 12, 202643 d10-Q——-$0.410.2%
Q1 2026Mar 31, 2026May 12, 2026 · after-hoursMay 12, 202642 d10-Q——-$0.5716.9%
FY 2025
Q4 2025derivedDec 31, 2025Mar 5, 2026 · after-hoursMar 5, 202664 d10-K———+11.1%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 12, 202543 d10-Q——-$0.5312.0%
Q2 2025Jun 30, 2025Aug 7, 2025 · after-hoursAug 7, 202538 d10-Q——-$0.442.6%
Q1 2025Mar 31, 2025May 12, 2025 · after-hoursMay 12, 202542 d10-Q——-$0.4011.6%
FY 2024
Q4 2024derivedDec 31, 2024Mar 6, 2025 · after-hoursMar 6, 202565 d10-K———0.8%
Q3 2024Sep 30, 2024Nov 7, 2024 · after-hoursNov 7, 202438 d10-Q——-$0.37+1.6%
Q2 2024Jun 30, 2024Aug 7, 2024 · after-hoursAug 7, 202438 d10-Q——-$0.48—
Q1 2024Mar 31, 2024May 14, 2024 · after-hoursMay 14, 202444 d10-Q——-$0.75—
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 9, 2026453807
10-QAug 12, 2026347021
10-QMay 12, 2026219678
10-KMar 5, 2026094159
10-QNov 12, 2025277815
10-QAug 7, 2025105123
10-QMay 12, 2025069367
10-KMar 6, 2025034808
10-QNov 7, 2024123447
10-QAug 7, 2024092914

Provenance

ProvenanceData status and checks

Atea Pharmaceuticals, Inc. · CIK 1593899 · Engraved from SEC EDGAR